Gene expression differences in lungs of mice during secondary immune responses to respiratory syncytial virus infection

Journal of Virology

Volumn 84, Issue 18, 2010, Pages 9584-9594

  Schuurhof, Annemieke ^a,b   Bont, Louis ^b   Pennings, Jeroen L A ^a   Hodemaekers, Hennie M ^a   Wester, Piet W ^a   Buisman, Annemarie ^a   De Rond, Lia C G H ^a   Widjojoatmodjo, Myra N ^c   Luytjes, Willem ^c   Kimpen, Jan L L ^b   Janssen, Riny ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INNATE IMMUNITY; LUNG; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POLARIZATION; PRIMARY INFECTION; PRIORITY JOURNAL; REINFECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TH2 CELL; VACCINATION; VIRUS GENE; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; CYTOCHEMISTRY; DNA MICROARRAY; GENE EXPRESSION PROFILING; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; PATHOLOGY; TIME; VIROLOGY;

ANIMALS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTOCYTOCHEMISTRY; LUNG; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; TH2 CELLS; TIME FACTORS; VIRAL LOAD;

EID: 77956041872     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00302-10     Document Type: Article

References (45)

1. Bloemers, B. L., A. M. van Furth, M. E. Weijerman, R. J. Gemke, C. J. Broers, E. K. van den, J. L. Kimpen, J. L. Strengers, and L. J. Bont. 2007. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis - a prospective birth-cohort study. Pediatrics 120:e1076-e1081.
2. Boelen, A., A. Andeweg, J. Kwakkel, W. Lokhorst, T. Bestebroer, J. Dormans, and T. Kimman. 2000. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine 19:982-991.
3. Boelen, A., J. Kwakkel, M. Barends, L. de Rond, J. Dormans, and T. Kimman. 2002. Effect of lack of interleukin-4, interleukin-12, interleukin-18, or the interferon-gamma receptor on virus replication, cytokine response, and lung pathology during respiratory syncytial virus infection in mice. J. Med. Virol. 66:552-560.
4. Castilow, E. M., M. R. Olson, and S. M. Varga. 2007. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol. Res. 39: 225-239.
5. Connors, M., N. A. Giese, A. B. Kulkarni, C. Y. Firestone, H. C. Morse III, and B. R. Murphy. 1994. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68:5321-5325.
6. Connors, M., A. B. Kulkarni, C. Y. Firestone, K. L. Holmes, H. C. Morse III, A. V. Sotnikov, and B. R. Murphy. 1992. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J. Virol. 66:7444-7451.
7. Empey, K. M., R. S. Peebles, Jr., and J. K. Kolls. 2010. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin. Infect. Dis. 50:1258-1267.
8. Falsey, A. R., C. K. Cunningham, W. H. Barker, R. W. Kouides, J. B. Yuen, M. Menegus, L. B. Weiner, C. A. Bonville, and R. F. Betts. 1995. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172:389-394.
9. Fjaerli, H. O., G. Bukholm, A. Krog, C. Skjaeret, M. Holden, and B. Nakstad. 2006. Whole blood gene expression in infants with respiratory syncytial virus bronchiolitis. BMC Infect. Dis. 6:175.
10. Fjaerli, H. O., G. Bukholm, C. Skjaeret, M. Holden, and B. Nakstad. 2007. Cord blood gene expression in infants hospitalized with respiratory syncytial virus bronchiolitis. J. Infect. Dis. 196:394-404.
11. Graham, B. S., T. R. Johnson, and R. S. Peebles. 2000. Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology 48:237-247.
12. Graham, B. S., M. D. Perkins, P. F. Wright, and D. T. Karzon. 1988. Primary respiratory syncytial virus infection in mice. J. Med. Virol. 26:153-162.
13. Guidry, G. G., C. A. Black-Payne, D. K. Payne, R. M. Jamison, R. B. George, and J. A. Bocchini, Jr. 1991. Respiratory syncytial virus infection among intubated adults in a university medical intensive care unit. Chest 100:1377-1384.
14. Hall, C. B., G. A. Weinberg, M. K. Iwane, A. K. Blumkin, K. M. Edwards, M. A. Staat, P. Auinger, M. R. Griffin, K. A. Poehling, D. Erdman, C. G. Grijalva, Y. Zhu, and P. Szilagyi. 2009. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360:588-598.
15. Hoebee, B., L. Bont, E. Rietveld, M. van Oosten, H. M. Hodemaekers, N. J. Nagelkerke, H. J. Neijens, J. L. Kimpen, and T. G. Kimman. 2004. Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis. J. Infect. Dis. 189:239-247.
16. Hoebee, B., E. Rietveld, L. Bont, M. Oosten, H. M. Hodemaekers, N. J. Nagelkerke, H. J. Neijens, J. L. Kimpen, and T. G. Kimman. 2003. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor alpha polymorphisms. J. Infect. Dis. 187:2-11.
17. Huang, D. W., B. T. Sherman, and R. A. Lempicki. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4:44-57.
18. Huang, Y. C., Z. Li, X. Hyseni, M. Schmitt, R. B. Devlin, E. D. Karoly, and J. M. Soukup. 2008. Identification of gene biomarkers for respiratory syncytial virus infection in a bronchial epithelial cell line. Genomic Med. 2:113-125.
19. Hussell, T., A. Georgiou, T. E. Sparer, S. Matthews, P. Pala, and P. J. Openshaw. 1998. Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. J. Immunol. 161:6215-6222.
20. Janssen, R., L. Bont, C. L. Siezen, H. M. Hodemaekers, M. J. Ermers, G. Doornbos, R. van 't Slot, C. Wijmenga, J. J. Goeman, J. L. Kimpen, H. C. van Houwelingen, T. G. Kimman, and B. Hoebee. 2007. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J. Infect. Dis. 196:826-834.
21. Janssen, R., J. Pennings, H. Hodemaekers, A. Buisman, M. van Oosten, L. de Rond, K. Ozturk, J. Dormans, T. Kimman, and B. Hoebee. 2007. Host transcription profiles upon primary respiratory syncytial virus infection. J. Virol. 81:5958-5967. (Pubitemid 46847032)
22. Johnson, T. R., and B. S. Graham. 1999. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J. Virol. 73:8485-8495.
23. Johnson, T. R., R. A. Parker, J. E. Johnson, and B. S. Graham. 2003. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J. Immunol. 170:2037-2045.
24. Karron, R. A., P. F. Wright, R. B. Belshe, B. Thumar, R. Casey, F. Newman, F. P. Polack, V. B. Randolph, A. Deatly, J. Hackell, W. Gruber, B. R. Murphy, and P. L. Collins. 2005. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191:1093-1104.
25. Reference deleted.
26. Kong, X., H. San Juan, M. Kumar, A. K. Behera, A. Mohapatra, G. R. Hellermann, S. Mane, R. F. Lockey, and S. S. Mohapatra. 2003. Respiratory syncytial virus infection activates STAT signaling in human epithelial cells. Biochem. Biophys. Res. Commun. 306:616-622.
27. Kuperman, D. A., C. C. Lewis, P. G. Woodruff, M. W. Rodriguez, Y. H. Yang, G. M. Dolganov, J. V. Fahy, and D. J. Erle. 2005. Dissecting asthma using focused transgenic modeling and functional genomics. J. Allergy Clin. Immunol. 116:305-311.
28. Martinez, I., L. Lombardia, B. Garcia-Barreno, O. Dominguez, and J. A. Melero. 2007. Distinct gene subsets are induced at different time points after human respiratory syncytial virus infection of A549 cells. J. Gen. Virol. 88:570-581.
29. McNamara, P. S., and R. L. Smyth. 2002. The pathogenesis of respiratory syncytial virus disease in childhood. Br. Med. Bull. 61:13-28.
30. Meissner, H. C. 2003. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 22:S40-S44.
31. Meyerholz, D. K., M. A. Griffin, E. M. Castilow, and S. M. Varga. 2009. Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model. Toxicol. Pathol. 37:249-255.
32. Openshaw, P. J., and J. S. Tregoning. 2005. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin. Microbiol. Rev. 18:541-555.
33. Pribul, P. K., J. Harker, B. Wang, H. Wang, J. S. Tregoning, J. Schwarze, and P. J. Openshaw. 2008. Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J. Virol. 82:4441-4448.
34. R Development Core Team. 2009. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
35. Reed, J. L., Y. A. Brewah, T. Delaney, T. Welliver, T. Burwell, E. Benjamin, E. Kuta, A. Kozhich, L. McKinney, J. Suzich, P. A. Kiener, L. Avendano, L. Velozo, A. Humbles, R. C. Welliver, Sr., and A. J. Coyle. 2008. Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J. Infect. Dis. 198:1783-1793.
36. Schmidt, A. C. 2007. Progress in respiratory virus vaccine development. Semin. Respir. Crit. Care Med. 28:243-252.
37. Simoes, E. A., and X. Carbonell-Estrany. 2003. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr. Infect. Dis. J. 22:S13-S18.
38. Tang, R. S., R. R. Spaete, M. W. Thompson, M. MacPhail, J. M. Guzzetta, P. C. Ryan, K. Reisinger, P. Chandler, M. Hilty, R. E. Walker, M. M. Gomez, and G. A. Losonsky. 2008. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine 26:6373-6382.
39. Tang, Y. W., and B. S. Graham. 1994. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J. Clin. Invest. 94:1953-1958.
40. Teng, M. N., S. S. Whitehead, and P. L. Collins. 2001. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 289:283-296.
41. van Drunen Littel-van den Hurk, S., J. W. Mapletoft, N. Arsic, and J. Kovacs-Nolan. 2007. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev. Med. Virol. 17:5-34.
42. Waris, M. E., C. Tsou, D. D. Erdman, S. R. Zaki, and L. J. Anderson. 1996. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70:2852-2860.
43. Widjojoatmodjo, M. N., J. Boes, M. van Bers, Y. van Remmerden, P. J. M. Roholl, and W. Luytjes. 2010. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virol. J. 7:114.
44. Zaas, A. K., M. Chen, J. Varkey, T. Veldman, A. O. Hero, III, J. Lucas, Y. Huang, R. Turner, A. Gilbert, R. Lambkin-Williams, N. C. Oien, B. Nicholson, S. Kingsmore, L. Carin, C. W. Woods, and G. S. Ginsburg. 2009. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 6:207-217.
45. Zhang, Y., M. Jamaluddin, S. Wang, B. Tian, R. P. Garofalo, A. Casola, and A. R. Brasier. 2003. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J. Virol. 77:5933-5947.